research Lokivetmab improved pruritus in a dog with cutaneous epitheliotropic lymphoma
Lokivetmab reduced itching in a dog with skin lymphoma.
Search
for
Sort by
Research
750-780 / 1000+ results research Comparative study between fractional carbon dioxide laser vs intralesional steroid injection in treatment of alopecia areata
FCO2 laser is a better treatment for alopecia areata than intralesional steroids.
research Exogenous IL-27 prevents the development of alopecia areata
IL-27 can prevent hair loss in alopecia areata.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research LB789 Novel IFNγ aptamer TAGX-0003 protected hair follicles from immune privilege collapse and reversed Alopecia Areata like phenotype in humanized mouse model
TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
research Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata
Baricitinib shows promise in treating severe hair loss.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Dovobet ointment under occlusion overnight for troublesome scalp psoriasis
Dovobet ointment used overnight effectively reduces scalp psoriasis severity and itch.
research Direct quantitative digital autoradiography of testosterone metabolites in the pilosebaceous unit: an environmentally advantageous trace radioactive technology
The method accurately measures testosterone metabolites with high sensitivity and low environmental impact.
research Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata
Higher IL-17A levels indicate more severe alopecia areata.
research Interferon alfa-2a in the treatment of cutaneous T cell lymphoma
Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.
research Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis
Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
research Ablative 2940 nm Er: YAG fractional laser for male androgenetic alopecia
research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research Treatment of Alopecia Areata with Anti-Interferon-γ Antibodies
Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.
research JAK-centric explainable few-shot gene-expression diagnosis framework for alopecia via MultiPLIER priors and relation-style set-to-set comparison
A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.
research Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research Intralesional Triamcinolone Acetonide in the Treatment of Traction Alopecia
Intralesional triamcinolone acetonide is effective and safe for treating early to mid-stage traction alopecia.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
The document's conclusion cannot be provided because the content is not available.
research A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System
JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.
research Injectable Platelet-, Leukocyte-, and Fibrin-Rich Plasma (iL-PRF) in the Management of Androgenetic Alopecia
iL-PRF treatment improves hair growth for androgenetic alopecia.
research Emerging role of ILK and ELMO2 in the integration of adhesion and migration pathways
ILK and ELMO2 help cells move and stick together, important for wound healing and hair growth.
research LB1777 A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
Farudodstat may help treat alopecia areata by protecting hair follicles.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
Blocking TYK2 might be a new way to treat hair loss from alopecia areata.